
UK first to approve Rotop's prostate cancer imaging agent
The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK said it has given a world-first approval to Rotop's trofolastat, a PSMA-targeting agent for detecting lesions in men with prostate cancer. The drug – also known as RoTecPSMA ( …